Shaping the Future of Human Health
Innovation is the lifeblood of medical advancement.
This is what we believe. This is what drives us.
What We Do
Our mission is to advance human health worldwide by forging stronger alliances among innovators, industry and government.
Why We Do It
We are invested in making a meaningful difference in the lives of patients and their families around the globe.
We like to think our headquarters are in Silicon Valley, but our home is the world. We are a global hub for novel thinking and creation. Providing a bold model for shaping the future of human health, guided by a focused, comprehensive vision.
As a nonprofit in the medical technology space, we are unique by nature. And we’ve leveraged our distinctive status to create an unmatched environment, where medtech community stakeholders converge to transform healthcare. Together, innovating visionary approaches to address unmet needs.
Our Guiding Principles
Who We Work With
The medical technology ecosystem is shaped by a variety of interconnected constituents—private and public, financial and philanthropic, academic and industrial. Each with unique viewpoints and interests. Our years of experience in this dynamic space have allowed us to develop deep and lasting relationships with many of these stakeholders. We consistently strive to grow and expand our alliances with our fellow participants in the medtech ecosystem. Our mission is to advance human health worldwide by facilitating the collaboration between these groups. In short, sharing a commitment to serve humanity.
“Fogarty Innovation offers holistic service to multiple constituents that are important to the goal of success in the medtech ecosystem — entrepreneurs, regulators, funders, etc. … This is critically important because I see lots of situations where entrepreneurs feel tension with agencies because of lack of exposure … FI has a lot to offer — more knowledge and sector-specific insights than many other incubators out there.”
– Venture Capitalist
The growing list of groups with whom we are proud to actively collaborate includes:
Medtech Advocacy Groups
Other Global Innovation Programs
The Investment Community
Successful innovation requires creativity in thinking. It demands the ability to identify and objectively consider concepts and solutions that are broader than any one person can conceive. That’s why we firmly believe the diversity of innovative ideas is grounded in the diversity of the individuals working together. To this end, we are committed to respecting and bringing together a broad range of groups. Inspired and empowered to explore, identify and pursue new and better ways of tackling challenges. Maximizing our collective impact through the synergy of diversity.
Join Our Journey
We are all innovators, and we have something novel to bring to life—whether an innovative idea, a new technology or a strong belief that there must be a better way. If healthcare is your passion—and you’re driven to shape its future—we encourage you to educate yourself about Fogarty Innovation’s audacious vision. We invite you to connect with us to make a difference in the medical technology ecosystem. And we hope you’ll join us as we seek to inspire innovation that advances human health. Help us turn possibilities into realities. Please read on, and contact us to begin your journey.
The cultivation of medical technology companies at various stages of development is at the heart of Fogarty Innovation’s mission, and the core of our history. From day one, we have teamed with medtech pioneers through our tailored incubation and acceleration programs. Get to know some of our current entrepreneurs and the groundbreaking ideas we are helping them translate into game-changing solutions for patients worldwide.
Autoimmune diseases are the third most common category of disease in the United States after cancer and heart disease. According to the National Institutes of Health, autoimmune diseases affect up to 27 million people in the US alone. Boomerang Medical is a bioelectronic medicine company developing technology to advance the treatment of autoimmune diseases by harnessing the body’s own “peripheral wiring” in order to manage inflammation and immune response. Boomerang Medical is backed by Arboretum Ventures, a venture capital firm specializing in companies that improve patient outcomes and reduce healthcare system costs. Boomerang Medical is also a Company-In-Residence at Fogarty Innovation, a leading Silicon Valley educational incubator focused on visionary approaches that address unmet needs in the rapidly evolving medtech landscape.
While many of our vital signs are easily obtained, the one test that doctors rely on to make the majority of their diagnoses—the blood test—can take hours, if not days, for results. Chronus Health has developed a portable device that provides lab results in minutes, allowing for real-time diagnosis and thus promising to dramatically improve time-to-care and patient outcomes. The startup has focused its initial efforts on complete blood count (CBC) and comprehensive metabolic panel (CMP), which account for 50 percent of all blood tests performed in the United States.
Current chronic therapies for short bowel syndrome (SBS), a malabsorption disorder caused by the lack of a functional small intestine, include expensive medication and intestinal surgery. These approaches have low success rates and a staggering average 5-year cost of care of $1.6 million per patient. Eclipse Regenesis is developing the first restorative therapy for pediatric and adult SBS patients with the Eclipse XL1 Distraction Enterogenesis System, which harnesses the body’s own tissue regenerative capabilities to produce new, fully functional intestine. The startup has raised a seed round of funding, been awarded numerous grants, has a growing IP portfolio and has been published in over 20 peer-reviewed journal articles.
Skin cancer is the most common form of malignancy, with more individuals diagnosed each year than for all other cancers combined. For the last 150 years these malignancies have required an invasive biopsy for diagnosis, but Enspectra is leading a digital transformation in pathology by imaging real-time cellular anatomy in living tissue, without cuts or stains.
As the adoption of telehealth increases, on-demand testing is no longer confined to healthcare settings. Everyplace is aiming to turn any location into a point-of-care lab with a self-service diagnostic kiosk that enables patient-initiated testing in community-based settings. It is designing simple, reliable, contactless patient-initiated testing to facilitate on-demand diagnostics as a complement to telehealth across a range of routine tests.
More than 110 million people worldwide suffer from non-healing, open wounds. High costs and overly complex technology severely limit, if not eliminate, access to advanced wound care technology. Healyx Labs is developing the lowest-cost and easiest-to-use wound vacuum technology for price-sensitive and underserved markets.
One hundred seventy-eight million adults in the United States are missing at least one tooth, and a surprising 40 million are missing all their teeth. Currently, dental implants are the top choice of treatment, yet less than two percent of those impacted by tooth loss are able to reap the benefits due to limited accessibility, high cost, high risk and long treatment time. iDentical is leveraging the latest 3D technology to offer a safer, faster and more affordable solution through its drill-free, non-invasive dental implants.
Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed an obstetrics and gynecology (OB-GYN) platform of medical devices: the first, Prep, is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time; the second, Milli, is helping treat pelvic pain and dyspareunia.
More than 36 million patients in the U.S. suffer from chronic rhinosinusitis. In fact, the condition accounts for 1 to 2% of all physician visits and is associated with $7 to 12 billion in direct U.S. healthcare costs per year. Nasal steroid sprays are typically prescribed as standard of care, but are only partially effective as they cannot reach beyond the anterior portion of the nasal cavity. Maximal medical therapy (sprays and pills) fail in 50% of patients, leaving them with the options of taking repetitive systemic drugs with serious side effects, having expensive, invasive procedures or continuing to suffer without sufficient treatment. Nasus Medical is developing solutions for improved intra-nasal drug delivery through an innovative technology that is designed for patients to treat themselves at home, early in the pathway.
Ultrasound is a key tool for diagnosing potentially life-threatening problems, but patients too often die before they reach a facility. UltraSight facilitates point-of-care ultrasound in the cardiac imaging space by offering real-time on-screen guidance and quality assessment through a layer of intelligence that simplifies and standardizes ultrasound cardiac scanning.
Latest Blogs and Videos
Now in its sixth year, the Ferolyn Fellowship continues its strong trajectory, and in a recent lively virtual event it celebrated the success of its most recent class of...
The 23rd Annual Thomas J. Fogarty Lecture was honored to feature Lisa Earnhardt, executive vice president of medical devices at Abbott, sharing her views on “Health Innovation:...
Our motto at Fogarty Innovation is “Innovation is best learned by doing.” It’s something you see at the organization every day, and that includes our incubation and...